$EYEN
EYENOVIA, INC.

2024 Q3 Form 10-Q Financial Statement

#000141057824001425 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $1.625K $22.63K
YoY Change 35.64%
Cost Of Revenue $132.5K $490.4K
YoY Change 10961.94%
Gross Profit -$130.9K -$467.7K
YoY Change
Gross Profit Margin -8055.2% -2067.34%
Selling, General & Admin $3.729M $3.759M
YoY Change 26.84% 19.33%
% of Gross Profit
Research & Development $3.472M $4.597M
YoY Change -2.97% 63.54%
% of Gross Profit
Depreciation & Amortization $287.5K $295.4K
YoY Change -10.16% 137.93%
% of Gross Profit
Operating Expenses $7.201M $11.22M
YoY Change 10.44% 88.24%
Operating Profit -$7.332M -$11.69M
YoY Change 12.45% 96.08%
Interest Expense -$557.1K $631.7K
YoY Change -182.02% 13.2%
% of Operating Profit
Other Income/Expense, Net -$555.9K $634.6K
YoY Change -32.08% 431.31%
Pretax Income -$7.888M -$11.05M
YoY Change 7.46% 77.71%
Income Tax
% Of Pretax Income
Net Earnings -$7.888M -$11.05M
YoY Change 7.48% 77.83%
Net Earnings / Revenue -485406.34% -48856.13%
Basic Earnings Per Share -$0.11 -$0.21
Diluted Earnings Per Share -$0.11 -$0.21
COMMON SHARES
Basic Shares Outstanding 64.06M 53.87M
Diluted Shares Outstanding 69.56M 53.12M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.188M $2.301M
YoY Change -65.27% -86.83%
Cash & Equivalents $7.200M $2.300M
Short-Term Investments
Other Short-Term Assets $1.108M $1.500M
YoY Change -77.3% -68.31%
Inventory $2.967M $3.052M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.69M $7.284M
YoY Change -55.94% -68.71%
LONG-TERM ASSETS
Property, Plant & Equipment $2.752M $3.041M
YoY Change -22.06% -17.76%
Goodwill
YoY Change
Intangibles $6.123M $6.123M
YoY Change 188.42%
Long-Term Investments
YoY Change
Other Assets $955.5K $1.138M
YoY Change 38.48% 341.14%
Total Long-Term Assets $11.11M $11.71M
YoY Change 33.29% 92.93%
TOTAL ASSETS
Total Short-Term Assets $11.69M $7.284M
Total Long-Term Assets $11.11M $11.71M
Total Assets $22.80M $18.99M
YoY Change -34.62% -35.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.574M $1.437M
YoY Change 10.37% 9.44%
Accrued Expenses $4.741M $4.833M
YoY Change 130.13% 177.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.429M $9.545M
YoY Change 213.27% 907.78%
Total Short-Term Liabilities $15.78M $15.85M
YoY Change 141.02% 289.96%
LONG-TERM LIABILITIES
Long-Term Debt $2.141M $4.532M
YoY Change -80.71% -65.6%
Other Long-Term Liabilities $1.153M $983.8K
YoY Change -19.95% -37.9%
Total Long-Term Liabilities $3.294M $5.516M
YoY Change -73.73% -62.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.78M $15.85M
Total Long-Term Liabilities $3.294M $5.516M
Total Liabilities $19.08M $21.36M
YoY Change -0.05% 13.49%
SHAREHOLDERS EQUITY
Retained Earnings -$175.4M -$167.5M
YoY Change 27.54% 28.66%
Common Stock $8.638K $5.582K
YoY Change 101.35% 46.24%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00 $0.00
YoY Change -100.0% -100.0%
Treasury Stock Shares
Shareholders Equity $3.719M -$2.370M
YoY Change
Total Liabilities & Shareholders Equity $22.80M $18.99M
YoY Change -34.62% -35.27%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.888M -$11.05M
YoY Change 7.48% 77.83%
Depreciation, Depletion And Amortization $287.5K $295.4K
YoY Change -10.16% 137.93%
Cash From Operating Activities -$5.944M -$8.174M
YoY Change 1.78% 73.38%
INVESTING ACTIVITIES
Capital Expenditures $1.630K $45.74K
YoY Change -99.72% -96.19%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.630K -$45.74K
YoY Change -99.9% -96.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.83M 2.545M
YoY Change 0.49% -49.11%
NET CHANGE
Cash From Operating Activities -5.944M -8.174M
Cash From Investing Activities -1.630K -45.74K
Cash From Financing Activities 10.83M 2.545M
Net Change In Cash 4.887M -5.675M
YoY Change 51.31% 468.52%
FREE CASH FLOW
Cash From Operating Activities -$5.944M -$8.174M
Capital Expenditures $1.630K $45.74K
Free Cash Flow -$5.945M -$8.220M
YoY Change -7.39% 38.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001682639
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55817921
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45553026
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38365
dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
393-6684
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EYEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64059440
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2300852
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14849057
CY2024Q2 us-gaap Inventory Net
InventoryNet
3052142
CY2023Q4 us-gaap Inventory Net
InventoryNet
109798
CY2024Q2 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
412140
CY2023Q4 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
4256793
CY2024Q2 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
124173
CY2023Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
123833
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1506
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1394313
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1365731
CY2024Q2 us-gaap Assets Current
AssetsCurrent
7283620
CY2023Q4 us-gaap Assets Current
AssetsCurrent
20706718
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3041462
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3374384
CY2024Q2 us-gaap Deferred Costs
DeferredCosts
170632
CY2024Q2 eyen Security Deposits
SecurityDeposits
197168
CY2023Q4 eyen Security Deposits
SecurityDeposits
197168
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6122945
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2122945
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
58693
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1408999
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1666718
CY2024Q2 eyen Equipment Deposits
EquipmentDeposits
711441
CY2023Q4 eyen Equipment Deposits
EquipmentDeposits
711441
CY2024Q2 us-gaap Assets
Assets
18994960
CY2023Q4 us-gaap Assets
Assets
28779374
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1436665
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1753172
CY2024Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1278178
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1658613
CY2024Q2 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2988128
CY2023Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
287928
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
600379
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
501250
CY2024Q2 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
692567
CY2023Q4 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
503914
CY2024Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
8730043
CY2023Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
5329419
CY2024Q2 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
18117
CY2023Q4 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
0
CY2024Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
815216
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
15848609
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9530382
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
983839
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1292667
CY2024Q2 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
0
CY2023Q4 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
448367
CY2024Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
637500
CY2023Q4 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
4355800
CY2024Q2 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
271752
CY2023Q4 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
398569
CY2024Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3894915
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4601431
CY2024Q2 us-gaap Liabilities
Liabilities
21364863
CY2023Q4 us-gaap Liabilities
Liabilities
19780280
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55817921
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45553026
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
5582
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4555
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165091874
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
154486098
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167467359
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145491559
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2369903
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8999094
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18994960
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28779374
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22625
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27618
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
490361
us-gaap Cost Of Revenue
CostOfRevenue
693388
CY2024Q2 us-gaap Gross Profit
GrossProfit
-467736
us-gaap Gross Profit
GrossProfit
-665770
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4597173
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2811061
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9028774
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5333011
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3758835
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3149809
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7396024
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6086695
CY2024Q2 eyen Reacquisition Of License Rights
ReacquisitionOfLicenseRights
2864600
eyen Reacquisition Of License Rights
ReacquisitionOfLicenseRights
4864600
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
11220608
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5960870
us-gaap Operating Expenses
OperatingExpenses
21289398
us-gaap Operating Expenses
OperatingExpenses
11419706
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11688344
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5960870
us-gaap Operating Income Loss
OperatingIncomeLoss
-21955168
us-gaap Operating Income Loss
OperatingIncomeLoss
-11419706
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2980
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
119450
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-94578
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
190443
CY2024Q2 eyen Change In Fair Value Of Equity Consideration Payable
ChangeInFairValueOfEquityConsiderationPayable
-1240800
eyen Change In Fair Value Of Equity Consideration Payable
ChangeInFairValueOfEquityConsiderationPayable
-1240800
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
674001
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
558003
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1352659
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1012006
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
64866
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
183563
us-gaap Investment Income Interest
InvestmentIncomeInterest
185805
us-gaap Investment Income Interest
InvestmentIncomeInterest
286043
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
634645
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-254990
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20632
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-535520
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11053699
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6215860
us-gaap Net Income Loss
NetIncomeLoss
-21975800
us-gaap Net Income Loss
NetIncomeLoss
-11955226
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53121760
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53121760
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38093826
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38093826
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49864275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49864275
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37753694
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37753694
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8999094
CY2024Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3194547
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
546232
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10922101
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1817772
CY2024Q2 eyen Stock Issued At Registered Direct Offering During Period Value New Issues
StockIssuedAtRegisteredDirectOfferingDuringPeriodValueNewIssues
1888829
CY2024Q2 eyen Stock Issued During Period Value Licensing Agreements
StockIssuedDuringPeriodValueLicensingAgreements
436809
CY2024Q2 eyen Stock Issued During Period Value Reacquisition Of Licensing Agreement
StockIssuedDuringPeriodValueReacquisitionOfLicensingAgreement
2322391
CY2024Q2 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
1676939
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
541056
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11053699
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2369903
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3499592
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
819064
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2023Q2 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
403120
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27200
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493632
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6215860
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10521947
us-gaap Net Income Loss
NetIncomeLoss
-21975800
us-gaap Net Income Loss
NetIncomeLoss
-11955226
us-gaap Share Based Compensation
ShareBasedCompensation
1087288
us-gaap Share Based Compensation
ShareBasedCompensation
1312696
eyen Change In Fair Value Of Equity Consideration Payable
ChangeInFairValueOfEquityConsiderationPayable
-1240800
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
543124
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
187267
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
368414
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
313446
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
85051
us-gaap Inventory Write Down
InventoryWriteDown
665770
eyen Non Cash Expenses On Reacquisition Of License Rights
NonCashExpensesOnReacquisitionOfLicenseRights
2864600
eyen Non Cash Rent Expense
NonCashRentExpense
257719
eyen Non Cash Rent Expense
NonCashRentExpense
280968
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-417775
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1514
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
340
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-754780
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
-377365
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1293395
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
140826
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1506
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1750
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-316508
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-115534
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-380435
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-734073
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-470432
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-139645
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-209699
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-284996
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18066228
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11673476
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
159853
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2122197
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-159853
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2122197
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
2000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
111171
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
5022151
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
4023414
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
150665
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
120702
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27200
eyen Proceeds From Issuance Of Debt And Equity Related Party
ProceedsFromIssuanceOfDebtAndEquityRelatedParty
5000000
eyen Payments Of Debt Issuance Costs Related Party
PaymentsOfDebtIssuanceCostsRelatedParty
125982
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1082439
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
403689
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5677876
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8400241
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12548205
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5395432
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14849057
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863520
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2300852
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17468088
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
984246
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
699116
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
505050
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
609140
eyen Accrual For Intangible Assets Milestone Obligation
AccrualForIntangibleAssetsMilestoneObligation
2000000
eyen Reclassification Of Deferred Clinical Supply Costs To Inventories
ReclassificationOfDeferredClinicalSupplyCostsToInventories
2801518
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
us-gaap Escrow Deposit Disbursements Related To Property Acquisition1
EscrowDepositDisbursementsRelatedToPropertyAcquisition1
468376
eyen Original Issue Discount On Notes Payable
OriginalIssueDiscountOnNotesPayable
212500
eyen Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
2
us-gaap Stock Issued1
StockIssued1
436809
eyen Stock Issued Value Reacquisition Of Licensing Agreement
StockIssuedValueReacquisitionOfLicensingAgreement
2322391
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
4
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2300000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167500000
us-gaap Net Income Loss
NetIncomeLoss
-22000000.0
us-gaap Net Income Loss
NetIncomeLoss
-12000000.0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11700000
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5450118
CY2024Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1573044
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
14243870
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
286236
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
30683
CY2024Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2765906
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
79115
CY2024Q2 us-gaap Inventory Net
InventoryNet
3052142
CY2023Q4 us-gaap Inventory Net
InventoryNet
109798
CY2024Q2 us-gaap Inventory Write Down
InventoryWriteDown
500000
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
0.0
us-gaap Inventory Write Down
InventoryWriteDown
700000
us-gaap Inventory Write Down
InventoryWriteDown
0.0
CY2024Q1 eyen Inventory Write Down Adjustments To List Price
InventoryWriteDownAdjustmentsToListPrice
200000
CY2024Q2 eyen Inventory Write Down Short Dated Inventory To Net Realizable Value
InventoryWriteDownShortDatedInventoryToNetRealizableValue
500000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11053699
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6215860
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21975800
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11955226
CY2024Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
52965044
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
38064215
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
49718045
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
37724083
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
156716
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29611
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
146230
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29611
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53121760
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53121760
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38093826
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38093826
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49864275
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49864275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37753694
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37753694
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.44
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20222576
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13686875
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
568997
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
167338
CY2024Q2 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
305981
CY2023Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
500684
CY2024Q2 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
65769
CY2023Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
421056
CY2024Q2 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
36765
CY2023Q4 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
123556
CY2024Q2 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
270401
CY2023Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
85938
CY2024Q2 eyen Prepaid Patent Expense
PrepaidPatentExpense
88483
CY2023Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
48409
CY2024Q2 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2023Q4 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2024Q2 eyen Prepaid Professional Fees Current
PrepaidProfessionalFeesCurrent
6667
CY2023Q4 eyen Prepaid Professional Fees Current
PrepaidProfessionalFeesCurrent
0
CY2024Q2 eyen Prepaid Board Of Directors Fees
PrepaidBoardOfDirectorsFees
32500
CY2023Q4 eyen Prepaid Board Of Directors Fees
PrepaidBoardOfDirectorsFees
0
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1394313
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1365731
CY2024Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
808787
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1302997
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
469391
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
355616
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1278178
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1658613
CY2024Q2 eyen Accrued Intangible Asset Milestone Obligation
AccruedIntangibleAssetMilestoneObligation
2000000
CY2024Q2 eyen Accrued Settlement On Defective Clinical Supply
AccruedSettlementOnDefectiveClinicalSupply
250000
CY2023Q4 eyen Accrued Settlement On Defective Clinical Supply
AccruedSettlementOnDefectiveClinicalSupply
100000
CY2024Q2 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
455520
CY2023Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
89872
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
239201
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
63028
CY2024Q2 eyen Credit Card Payable
CreditCardPayable
31967
CY2023Q4 eyen Credit Card Payable
CreditCardPayable
27193
CY2024Q2 eyen Accrued Franchise Tax
AccruedFranchiseTax
10000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1440
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7835
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2988128
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
287928
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
10255943
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
710684
CY2024Q2 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
9545259
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5833333
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
503914
CY2023Q4 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
5329419
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4804167
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
271752
CY2024Q2 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
4532415
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9804167
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
846936
CY2023Q4 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
8957231
CY2020Q4 eyen Written Notice Period For Termination Of Agreement
WrittenNoticePeriodForTerminationOfAgreement
P90D
us-gaap Operating Lease Payments
OperatingLeasePayments
209699
us-gaap Operating Lease Payments
OperatingLeasePayments
284996
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M2D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
364928
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
675400
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
560996
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214618
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1815942
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
231724
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1584218
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
600379
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
983839
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
eyen Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
4900000
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4128276
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
541056
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
493632
us-gaap Share Based Compensation
ShareBasedCompensation
1087288
us-gaap Share Based Compensation
ShareBasedCompensation
1312696
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
106019
CY2023Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
2.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
368886
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
0.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
106019
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
2.12
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
368886
CY2024Q2 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
0.65
eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
241764
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
2.17
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6599389
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y
CY2024Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4053359
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2358546
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2024Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.44
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.04
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.84
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.78
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2024Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
61706
CY2023Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
46196
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
164189
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
125164
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
eyen-20240630_cal.xml Edgar Link unprocessable
0001410578-24-001425-index-headers.html Edgar Link pending
0001410578-24-001425-index.html Edgar Link pending
0001410578-24-001425.txt Edgar Link pending
0001410578-24-001425-xbrl.zip Edgar Link pending
eyen-20240630.xsd Edgar Link pending
eyen-20240630x10q.htm Edgar Link pending
eyen-20240630xex31d1.htm Edgar Link pending
eyen-20240630xex31d2.htm Edgar Link pending
eyen-20240630xex32d1.htm Edgar Link pending
eyen-20240630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
eyen-20240630_def.xml Edgar Link unprocessable
eyen-20240630_lab.xml Edgar Link unprocessable
eyen-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eyen-20240630x10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending